133 related articles for article (PubMed ID: 28711730)
1. Purification and characterization of a long-acting ciliary neurotrophic factor via genetically fused with an albumin-binding domain.
Xu L; Zhang C; Liu L; Zhang Y; Wang Q; Wang J; Liu Y; Su Z
Protein Expr Purif; 2017 Nov; 139():14-20. PubMed ID: 28711730
[TBL] [Abstract][Full Text] [Related]
2. Ciliary neurotrophic factor fused to a protein transduction domain retains full neuroprotective activity in the absence of cytokine-like side effects.
Rezende AC; Peroni D; Vieira AS; Rogerio F; Talaisys RL; Costa FT; Langone F; Skaper SD; Negro A
J Neurochem; 2009 Jun; 109(6):1680-90. PubMed ID: 19457136
[TBL] [Abstract][Full Text] [Related]
3. Ciliary neurotrophic factor infused intracerebroventricularly shows reduced catabolic effects when linked to the TAT protein transduction domain.
Vieira AS; Rezende AC; Grigoletto J; Rogério F; Velloso LA; Skaper SD; Negro A; Langone F
J Neurochem; 2009 Sep; 110(5):1557-66. PubMed ID: 19573019
[TBL] [Abstract][Full Text] [Related]
4. High level soluble expression, purification, and characterization of human ciliary neuronotrophic factor in Escherichia coli by single protein production system.
Wang K; Zhou F; Zhu L; Zhu X; Zhang K; Zhu L
Protein Expr Purif; 2014 Apr; 96():8-13. PubMed ID: 24486790
[TBL] [Abstract][Full Text] [Related]
5. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
[TBL] [Abstract][Full Text] [Related]
6. High hydrostatic pressure enables almost 100% refolding of recombinant human ciliary neurotrophic factor from inclusion bodies at high concentration.
Wang Q; Liu Y; Zhang C; Guo F; Feng C; Li X; Shi H; Su Z
Protein Expr Purif; 2017 May; 133():152-159. PubMed ID: 28323167
[TBL] [Abstract][Full Text] [Related]
7. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
Ren Z; Zhao J; Cao X; Wang F
Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
[TBL] [Abstract][Full Text] [Related]
8. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
[TBL] [Abstract][Full Text] [Related]
9. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
10. [Purification and activity assay of HSA-AX15 (R13K) fusion protein expressed in Pichia pastoris].
Zhao HL; Xue C; Xiong XH; Zhang W; Yang BF; Liu ZM
Sheng Wu Gong Cheng Xue Bao; 2005 Mar; 21(2):254-8. PubMed ID: 16013485
[TBL] [Abstract][Full Text] [Related]
11. Development of long-acting ciliary neurotrophic factor by site-specific conjugation with different-sized polyethylene glycols and transferrin.
Zhang C; Yu R; Li Z; Feng C; Wang Q; Liu Y; Su Z
Int J Pharm; 2017 Aug; 529(1-2):275-284. PubMed ID: 28652173
[TBL] [Abstract][Full Text] [Related]
12. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
[TBL] [Abstract][Full Text] [Related]
13. Expression of biologically active mouse ciliary neutrophic factor (CNTF) and soluble CNTFRalpha in Escherichia coli and characterization of their functional specificities.
Cognet I; Guilhot F; Chevalier S; Guay-Giroux A; Bert A; Elson GC; Gascan H; Gauchat JF
Eur Cytokine Netw; 2004; 15(3):255-62. PubMed ID: 15542451
[TBL] [Abstract][Full Text] [Related]
14. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
[TBL] [Abstract][Full Text] [Related]
15. Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein.
Gapizov SS; Petrovskaya LE; Shingarova LN; Kryukova EA; Boldyreva EF; Lukashev EP; Yakimov SA; Svirshchevskaya EV; Dolgikh DA; Kirpichnikov MP
Biotechnol Appl Biochem; 2019 Jul; 66(4):617-625. PubMed ID: 31140614
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).
Penn RD; Kroin JS; York MM; Cedarbaum JM
Neurosurgery; 1997 Jan; 40(1):94-9; discussion 99-100. PubMed ID: 8971830
[TBL] [Abstract][Full Text] [Related]
17. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
Stork R; Müller D; Kontermann RE
Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
[TBL] [Abstract][Full Text] [Related]
18. Novel Bioconjugation Strategy Using Elevated Hydrostatic Pressure: A Case Study for the Site-Specific Attachment of Polyethylene Glycol (PEGylation) of Recombinant Human Ciliary Neurotrophic Factor.
Wang Q; Zhang C; Guo F; Li Z; Liu Y; Su Z
Bioconjug Chem; 2017 Nov; 28(11):2841-2848. PubMed ID: 29053917
[TBL] [Abstract][Full Text] [Related]
19. Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics.
Jacobs SA; Gibbs AC; Conk M; Yi F; Maguire D; Kane C; O'Neil KT
Protein Eng Des Sel; 2015 Oct; 28(10):385-93. PubMed ID: 26275855
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of subcutaneously administered recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: relation to parameters of the acute-phase response. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.
Clin Neuropharmacol; 1995 Dec; 18(6):500-14. PubMed ID: 8681311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
